IL6 and hepatocellular carcinoma: The ability of NVP-BEZ235 combined with IL-6 antibody to inhibit the invasion of HCC cells was more significant than that of the single drug group, indicating that cell motility of the single drug group was stronger than that of the combined drug group (Fig. 5C).